Recent News

• 04.25.2025 - Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
• 04.25.2025 - Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
• 03.04.2025 - Fourth Quarter and Full Year 2024 Financial and Operating Results
• 03.04.2025 - Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
• 03.04.2025 - Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
• 03.03.2025 - Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
• 03.03.2025 - Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
• 02.20.2025 - Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

Recent Filings

• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.07.2025 - 144 Report of proposed sale of securities
• 03.07.2025 - 144 Report of proposed sale of securities
• 03.07.2025 - 144 Report of proposed sale of securities
• 03.07.2025 - 144 Report of proposed sale of securities
• 03.04.2025 - 8-K Current report
• 03.04.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.04.2025 - 8-K Current report
• 03.04.2025 - 424B5 Prospectus [Rule 424(b)(5)]